Machine Learning Prediction of Parameters of Early Warning Scores in General Wards
Launched by KEPLER UNIVERSITY HOSPITAL · Aug 26, 2024
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how machine learning can help improve patient safety on general hospital wards. Currently, when patients are admitted, their health is monitored at certain times, but this approach might miss important changes in their condition. The goal of this study is to see if using advanced technology can help predict when a patient's health might worsen, allowing medical staff to respond more quickly and prevent serious complications.
To participate in this trial, you must be between the ages of 65 and 74 and be treated in a general hospital ward between October 2024 and October 2026. There are no specific exclusions, so if you meet the age requirement and are receiving care in the right time frame, you may be eligible. If you join, you can expect to contribute to important research that aims to enhance patient monitoring and safety, potentially benefiting many patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Treated in general ward between 2024-10-01 and 2026-10-31 at the study center.
- Exclusion Criteria:
- • None.
About Kepler University Hospital
Kepler University Hospital is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the hospital collaborates with multidisciplinary teams to conduct rigorous studies that aim to enhance treatment methodologies and improve patient outcomes. Leveraging its state-of-the-art facilities and commitment to excellence, Kepler University Hospital plays a pivotal role in translating scientific discoveries into practical applications, thereby contributing to the advancement of medical knowledge and the improvement of public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Thomas Tschoellitsch, MD
Principal Investigator
Johannes Kepler University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported